EBMT-EHA CAR-T 2019 | The importance of registering CAR T-cell patient data
Max Topp, MD University of Würzburg, Würzburg, Germany, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Topp discusses the importance of CAR T-cell toxicity data collection.
Transcript (edited for clarity):
I think the most important thing is just to support all the European countries in their efforts to record, to provide the data to registries in a well-controlled fashion. Because only if we capture the data, we learn something and can decipher who or which patient is at risk. Because currently the trials that have led to registration are based on a hundred patients. So that if we have collected data of let’s say, a thousand patients, we may learn something off that. So the data quality plays a very big part in that. And that is something that the health providers can provide funding for this extra activity, which is clearly not what you would do on the ground, in the hospital. But it helps to decipher the toxicities.
Get great new content delivered to your inboxSign up